JSJohn H. Stone

John H. Stone

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John H. Stone has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Solid malignancies among patients in the Wegener's granulomatosis etanercept trial

    by John H. Stone, Janet T. Holbrook, Matthew A. Marriott, Andrea K. Tibbs, Lourdes P. Sejismundo, Y.‐I. Min, Ulrich Specks, Peter A. Merkel, Robert Spiera, John C. Davis, et al.

    Objective: Etanercept is a soluble fusion protein designed to inhibit tumor necrosis factor (TNF). During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo‐controlled trial of etanercept given in addition to standard therapy for remission induction and maintenance, more solid malignancies were observed in the etanercept group than in the group treated with standard therapy alone. This study was undertaken to further explore the potential association between anti‐TNF therapy and the development of malignancy in these patients.Methods: One hundred eighty patients with active WG were enrolled and followed up for a median of 27 months. At enrollment, disease characteristics, treatment history, specific medical history items, and information about previous WG treatments and risk factors for malignancy were recorded. During the trial, the occurrence of malignancies and other adverse events was recorded prospectively.Results: All 6 solid malignancies observed during the WGET occurred in the etanercept group (P = 0.01 versus placebo group); based on a comparison of age‐ and sex‐specific incidence rates, 1.92 solid malignancies would have been expected in this group. The solid malignancies included 2 cases of mucinous adenocarcinoma of the colon, 1 each of metastatic cholangiocarcinoma, renal cell carcinoma, and breast carcinoma, and 1 recurrent liposarcoma. There were no differences between the 2 treatment groups in sex distribution, disease severity, personal or family history of cancer, or tobacco and alcohol use. The etanercept group was older at baseline and less likely to be newly diagnosed with WG at the time of randomization. Patients who developed solid tumors were older than patients who did not. All etanercept‐treated patients who developed solid tumors were also treated with cyclophosphamide during the trial. However, there were no differences between the groups in the amount of cyclophosphamide received during the trial or the percentage who had received cyclophosphamide before enrollment. There were also no differences in the mean duration of daily cyclophosphamide therapy or the maximum daily cyclophosphamide dosage before enrollment.Conclusion: Data from the WGET, the first substantial reported experience of the combined use of etanercept and cyclophosphamide in the treatment of WG, indicate that the combination of TNF inhibition and cyclophosphamide may heighten the risk of cancer beyond that observed with cyclophosphamide alone.


  • Churg-strauss syndrome presenting with salivary gland enlargement and respiratory distress

    by Francesco Boin, James J. Sciubba, John H. Stone


    • 1 January 2006
      • Vol. 69  (2) , 31-2

    Hearing voices.

    by John H Stone

  • New journal policy regarding registration of clinical trials

    by John H. Stone, Michael D. Lockshin, Patricia P. Katz, Edward H. Yelin


  • Open Access

    New journal policy regarding registration of clinical trials

    by John H. Stone, Michael D. Lockshin, Patricia P. Katz, Edward H. Yelin


  • Open Access

    Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)

    by Philip Seo, Yuan‐I. Min, Janet T. Holbrook, Gary S. Hoffman, Peter A. Merkel, Robert Spiera, John C. Davis, Steven R. Ytterberg, E. William St. Clair, W. Joseph McCune, et al.

    Objective: To analyze damage occurring in patients with Wegener's granulomatosis (WG) enrolled in the WG Etanercept Trial (WGET) and to correlate that damage with disease activity, adverse events, and quality of life.Methods: The Vasculitis Damage Index (VDI) was applied to all 180 patients at trial entry and every 6 months throughout the trial. Items of damage were analyzed by presumed etiology (i.e., secondary to WG, to therapy, or both) and time of occurrence. Spearman's rank correlation coefficients were calculated between VDI scores and the Birmingham Vasculitis Activity Score for WG (BVAS/WG), frequency of flares, number of adverse events, and the patients' quality‐of‐life assessments.Results: The mean VDI score was 1.3 at the study enrollment and 1.8 at the end of the trial. This increase was due to damage that occurred despite (or because of) therapy, including visual impairment, hearing loss, nasal blockade, pulmonary fibrosis, hypertension, renal insufficiency, peripheral neuropathy, gonadal failure, and diabetes mellitus. Only 11% of the enrolled patients had not sustained a single VDI item after 1 year of enrollment. When adjusted for baseline VDI, the baseline BVAS/WG correlated moderately well with the VDI score at 1 year (r = 0.20, P = 0.015). Increases in adjusted VDI scores also correlated with the number of adverse events, particularly among patients with limited WG (P = 0.06).Conclusion: Damage from both active disease and its treatment remain important problems for patients with WG. Despite the dramatic improvements in patient survival achieved over the last several decades, only a few patients with WG emerge from a period of active disease without sustaining some damage from the disease itself, its treatment, or both. An important measure of future therapeutic approaches will be their ability to reduce the damage accrued over time.


  • Open Access

    A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis

    by John H. Stone, Vinodh N. Rajapakse, Gary S. Hoffman, Ulrich Specks, Peter A. Merkel, Robert F. Spiera, John C. Davis, E. William St.Clair, Joseph McCune, Sally Ross, et al.


  • Human Monocytic Ehrlichiosis

    by John H. Stone, Kerry Dierberg, Ghazaleh Aram, J. Stephen Dumler

    Review from JAMA — Human Monocytic Ehrlichiosis — A 56-year-old man with a history of Wegener granulomatosis presented with 6 days of sinus congestion, fever, malaise, myalgias, episcleritis, and a morbilliform rash. An exacerbation of Wegener granulomatosis was the principal concern because of the frequency of flares in that disease. The patient developed acute renal failure, thrombocytopenia, transaminitis, and, finally, severe myocarditis that led to congestive heart failure. Additional history-taking and the evolution of his clinical features led to empirical treatment with doxycycline for human monocytic ehrlichiosis (HME). The diagnosis of HME was confirmed by both a polymerase chain reaction assay for Ehrlichia chaffeensis and by the demonstration of morulae within peripheral blood mononuclear cells. The patient improved promptly following institution of doxycycline, and his cardiac function returned to normal over a period of 4 months.